Search

Your search keyword '"Newell-Price, John"' showing total 150 results

Search Constraints

Start Over You searched for: Author "Newell-Price, John" Remove constraint Author: "Newell-Price, John" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
150 results on '"Newell-Price, John"'

Search Results

3. Changing the name of diabetes insipidus

4. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey

5. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study

6. Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol.

7. A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic–Pituitary–Adrenal Axis.

9. Biochemical control with dose reduction in chronic glucocorticoid therapy over 4 years: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH)

10. Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing's disease: A pooled analysis of LINC 3 and LINC 4

11. CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency

12. Morning cortisol levels in patients with established primary adrenal insufficiency

13. Participants aux Davidson's Principles and Practice of Medicine, 23eédition

14. Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus.

19. SAT304 Improved Biochemical Control With Dose Reduction In Chronic Glucocorticoid Therapy: A Phase III Extension Study Of Chronocort (Efmody) In The Treatment Of Congenital Adrenal Hyperplasia (CAH)

20. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis

21. Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium

22. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors

24. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

26. Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels

28. Natural history of non-functioning pituitary microadenomas - results from the UK NFPA consortium

29. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

30. Home Waking Salivary Cortisone to Screen for Adrenal Insufficiency

31. Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia

32. Diagnosis and management of hypertension in patients with Cushing's syndrome

33. RF09 | PSAT70 Comparison of Prednisolone Versus Modified-release Hydrocortisone (Efmody) in the Treatment of Congenital Adrenal Hyperplasia (CAH)

35. Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

36. PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat

37. LBMON62 Central Diabetes Insipidus From A Patients’ Perspective- From Management To Psychological Co-morbidities And Re-naming Of The Condition

39. Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

40. Blood pressure (BP) status in Congenital Adrenal Hyperplasia (CAH) – longitudinal analysis of real world data from the I-CAH registry

41. Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control

42. Natural history of non-functioning pituitary microadenomas - results from the UK NFA consortium

47. Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

48. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension

Catalog

Books, media, physical & digital resources